Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.
Findings from the preclinical study led by Shulin Li, Ph.D., professor of Pediatrics, and Amy Heimberger, M.D., professor of Neurosurgery, were published in the Jan. 25 online...
The University of Texas MD Anderson Cancer Center today named Rosanna Morris, RN, MBA, as chief operating officer (COO). With more than 20...
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly...
Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated
Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials, and associated downstream costs ranged from $6,320 to $56,845 on average, according to a new study from The University of Texas MD Anderson Cancer Center.
The researchers believe the findings, published today in JAMA Internal Medicine, reinforce...
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment...
By analyzing variations in the level of human papillomavirus (HPV) in head and neck cancers, researchers at The University of Texas MD Anderson...
John Mendelsohn, M.D., president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in...
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration...
The University of Texas MD Anderson Cancer Center and Ascentage Pharma Group, Inc. today announced a five-year strategic collaboration agreement...
MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic...
Waun Ki Hong, M.D., a trail-blazing physician-scientist and mentor whose clinical research innovations led to successful organ-sparing cancer...